Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
NCT ID: NCT01997424
Last Updated: 2021-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
340 participants
INTERVENTIONAL
2013-05-31
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Transient Elastography and Controlled Attenuation Parameter using the FibroScan
* blood examination including biochemical markers The statistically calculated sample size needed is 340 patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease
NCT01638832
Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.
NCT01985009
Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients
NCT04493814
Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus
NCT04232293
Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents
NCT03908294
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Controlled Attenuation Parameter (CAP), Echosens, Paris, France
FibroScan, Echosens, Paris, France
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
* Diabetes mellitus type 1 or 2
Exclusion Criteria
* Pregnancy or lactation
* Ascites
* Continued alcohol consumption (\> 21 drinks/week for male and \> 14 drinks/week for female patients)
* Chronic liver disease (viral hepatitis, autoimmune hepatitis, PBC, PSC, hemochromatosis, M Wilson)
* Hepatocellular carcinoma/ Liver metastasis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johann Wolfgang Goethe University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Georg Dultz
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mireen Friedrich-Rust, MD
Role: PRINCIPAL_INVESTIGATOR
Goethe University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Frankfurt
Frankfurt am Main, Hesse, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JWGUHMED1-007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.